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Absence of donor MHC antigen expression ameliorates chronic Despite dramatic improvements in the field of trans-
kidney allograft rejection. plantation, chronic rejection (CR) remains the leading
Background. In previous studies, we have demonstrated that cause of late graft failure [1]. While the pathophysiologya subset of mouse kidney allografts has prolonged survival with-
of CR has been debated, immunologic factors have beenout any immunosuppressive treatment. Chronic rejection (CR)
felt to play a critical role in the development of CR. Fordevelops in these long surviving grafts. The pathologic features
of CR in this model are similar to CR in human kidney grafts. example, CR has been strongly correlated with acute
Methods. To explore the role of donor major histocompati- rejection episodes [2–4] and the impact of acute rejection
bility complex (MHC) antigens in the development of CR, we
on CR development has been rising despite the introduc-performed vascularized kidney transplants using kidneys from
tion of newer immunosuppressive treatments [5]. Fur-donor mice that lack expression of both MHC class I and II
antigens (MHC/). thermore, several studies have demonstrated improved
Results. Survival was significantly improved in recipients of graft survival for living related allografts compared to
MHC/ allografts. This enhanced survival was associated cadaveric grafts [5, 6]. On the other hand, the failure ofwith higher glomerular filtration rate (GFR) in MHC/ allo-
CR to improve with immunosuppression suggests non-grafts (4.92  0.54 cc/min/kg) compared to controls (2.19 
immunologic factors are involved. These factors may0.63 cc/min/kg; P  0.004). The typical histologic features of
CR were markedly reduced in MHC/ allografts. Semiquan- include disparity between donor and recipient size, drug
titative histopathological scores for MHC/ grafts (13.3  nephrotoxicity, hypertension, and hyperlipidemia [re-
2.1) were significantly lower than in control allografts (19.0  viewed in 7]. Thus, the relative importance of antigen-1.0; P 0.04). Along with this improvement in structural abnor-
dependent mechanisms has not been quantitated.malities, significantly fewer CD4 T (38.3 cells/mm2 vs. 75.0
cells/mm2; P  0.008), CD8 T cells (38.7 vs. 96 cells/mm2, The rejection of transplanted tissues is triggered by the
respectively; P 0.008) and macrophages (60 vs. 134 cells/mm2, recognition of donor major histocompatibility complex
respectively; P  0.04) infiltrated MHC/ allografts com- (MHC) antigens. This recognition process activates hu-
pared to controls. The levels of intragraft cytokine mRNA
moral and cellular effector responses leading to graft in-expression also were reduced in MHC/ allografts compared
jury and destruction. Antigen recognition occurs via oneto control allografts. Finally, serum alloantibodies were virtu-
ally undetectable in recipients of MHC/ kidney allografts. of two mechanisms. In direct recognition, foreign anti-
Conclusions. Cell surface expression of donor MHC anti- gens are presented by foreign antigen presenting cells
gens promotes the development of CR. Donor antigen expres- (APCs). In indirect recognition, recipient T cells recog-sion promotes the accumulation of infiltrating cells in the graft
nize processed foreign antigens presented by recipientand the development of donor specific alloantibodies. Abroga-
tion of these responses is associated with improved graft sur- APCs. It is believed that the direct pathway predomi-
vival and reduced CR in MHC/ grafts. nantly mediates early acute rejection, as the graft con-
tains donor-derived APCs, expressing a high density of
MHC molecules available for presentation [reviewed in
8]. In contrast, indirect recognition may be more signifi-
cant in chronic rejection, where donor APCs are no longerKey words: chronic rejection, kidney, transplantation, MHC, mouse,
antibody, major histocompatibility complex antigens, late graft failure. present [9], a process that may be resistant to standard
immunosuppression. However, there is mounting evidenceReceived for publication October 28, 2001
that indirect recognition may be important in acute rejec-and in revised form February 7, 2002
Accepted for publication February 20, 2002 tion. For example, animals immunized with donor MHC
class II peptides rejected their grafts in an accelerated 2002 by the International Society of Nephrology
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fashion compared to recipients that had not been immu- DBA/2J] F1 animals (H-2d). In the experimental MHC/
allograft group, kidneys from MHC/ mice (H-2b)nized [10]. Further, skin allografts lacking MHC class II
are rapidly rejected, via indirect recognition of donor were transplanted into [BALB/c  DBA/2J] F1 recipi-
ents. In the non-rejecting isograft control group, kidneysMHC class I [11]. However, the relative roles of direct
versus indirect allorecognition in chronic rejection have from [BALB/c  DBA/2J] F1 donors were transplanted
into their littermates. Transplanted mice were studiednot yet been addressed.
In previous studies, we demonstrated that mouse kid- at six weeks following transplantation.
ney allografts transplanted across complete MHC dispar-
Measurement of kidney transplant functionities survive for prolonged periods of time [12, 13]. Renal
allografts in mice have severely reduced function com- To accurately assess kidney transplant function, clear-
ances of inulin and para-aminohippurate (PAH) werepared to non-rejecting isografts and develop a histologic
picture consistent with chronic rejection by 6 weeks post- measured as previously described [13] and used as mea-
sures of glomerular filtration rate (GFR) and renaltransplant [14]. In this study, we examined the effect of
reducing the inherent immunogenicity of the graft on plasma flow (RPF), respectively.
the course of CR. Our studies suggest that cell surface
Evaluation of allograft histomorphologyexpression of donor MHC antigens contribute to the
extent and severity of CR. Reduction in donor alloanti- Following the renal hemodynamic studies, animals were
sacrificed and kidneys were macrodissected. Sections ofgen expression suppresses the development of donor-
specific humoral responses and improves graft function transplant kidney were fixed in formalin and stained with
hematoxylin-eosin, Masson-trichrome and periodic acidand survival.
Schiff stains. A renal pathologist who was masked to the
experimental groups evaluated the sections.
METHODS
Animals Immunohistology
Immunopathology was performed as previously de-Major histocompatibility complex class I- and II-defi-
cient mice (MHC/) were obtained by breeding inbred scribed [14]. Briefly, kidney tissue was embedded in OCT
(Sakura, Torrance, CA, USA), snap frozen in pre-cooledAb-deficient mice (H-2b) [15] with inbred 2-microglob-
ulin–deficient mice (H-2b) [16]. C57BL/6 (H-2b) mice 2-methylbutane, and stored at 80C. Tissue sections
(4 mol/L) were cut with a cryostat, and mounted onpurchased from Jackson Laboratory (Bar Harbor, ME,
USA) and were used as control donors fully expressing positively charged microscope slides (Superfrost Plus,
Fisher Scientific, Pittsburgh, PA, USA) and stored atMHC antigens. [BALB/c  DBA/2J]F1 mice (Jackson
Laboratory) were used as recipients in all experiments. 80C in an airtight box. Sections were then air-dried,
and fixed for 10 minutes in 4C acetone (HPLC grade;All mice were maintained in the Durham VA Animal
Facility under AALAC guidelines. Fisher Scientific). Sections were then post-fixed for two
minutes in 100 mmol/L Tris-buffered 1% paraformalde-
Mouse kidney transplantation hyde containing 1 mmol/L ethylenediaminetetraacetic
acid (EDTA), pH 7.2, and rinsed with phosphate buf-Vascularized kidney transplants were performed in
mice as previously described [13]. Briefly, animals were fered saline (PBS) pH 7.2. Primary antibodies included
fluorescein-5-isothiocyanate (FITC)-conjugated poly-anesthetized with isoflurane and the donor kidney, ure-
ter, and bladder were harvested en bloc, including the clonal primary antibodies consisting of affinity purified
goat anti-murine IgG (FC, 	-specific; ICN Biomedicals,renal artery with a small aortic cuff and the renal vein
with a small caval cuff. These vascular cuffs were anasto- Costa Mesa, CA, USA), affinity purified goat F(ab
)2
anti-murine IgM (-specific; ICN), and goat anti mousemosed to the recipient abdominal aorta and vena cava,
respectively, below the level of the native renal vessels. CD3 (ICN) or rat monoclonal antibodies TIB126 (anti-
MHC class I), TIB120 (anti-MHC class II), GK1.5 (anti-Total ischemic time averaged 35 to 40 minutes. Donor
and recipient bladders were attached dome to dome. CD4), and 3.155 (anti-CD8) (prepared as hybridoma
supernatants; American Type Culture Collection, Rock-The right native kidney was removed at time of trans-
plant and the left native kidney was removed through a ville, MD, USA), 30-H122 (anti-Thy 1.2; Boehringer
Mannheim, Indianapolis, IN, USA), RA36B2 (anti-flank incision four days later. Overall surgical mortality
was approximately 20% and there were no significant B220), and M1/70HL (anti-CD11b/Mac-1; BD Phar-
Mingen, San Diego, CA, USA). For the non-labeleddifferences in peri-operative mortality between the ex-
perimental groups. primary antibodies, binding was detected with affinity-
purified fluorescein isothiocyanate-labeled goat anti-ratThree experimental groups were evaluated. In the con-
trol allograft group, donor kidneys from C57BL/6 mice IgG, followed by a secondary layer of affinity-isolated
FITC-rabbit anti-goat IgG (Cappel, Durham, NC, USA).(H-2b) were transplanted into fully allogeneic [BALB/c
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Primary antibody was applied to sections for 45 minutes gen). Ten micrograms of total RNA were assayed in each
at room temperature. Sections were rinsed and cover- sample using the RPA kit as outlined by the manufac-
slipped with a medium consisting of 25 mg/mL 1,4-dia- turer. The protected fragments were size-fractionated on
zabicyclo[2.2.2]octane (DABCO), 0.5 mg/mL 4,6-dia- the Quick-Point rapid DNA sequencing system (Novex,
midino-2-phenylindole (DAPI), and 50% glycerol in San Diego, CA). Dried gels were placed on Kodak XAR
PBS, pH 8.6, and stored in the dark at 4C. Digital images film (Rochester, NY, USA), with intensifying screens,
were obtained utilizing a high-resolution CCD digital for 24 to 120 hours at 70C. The intensity of autora-
camera (SPOT II; Diagnostic Instruments, Sterling diographic signal was quantitated by laser densitometry
Heights, MI, USA), and software mounted onto an (Molecular Dynamics, Sunnydale, CA, USA). The re-
epifluorescent microscope. sults were expressed as arbitrary densitometry units that
correspond to the area under the densitometric peak.Quantitative immunohistology
Results were normalized for levels of L32 expression.
Quantitative immunohistology was performed as pre-
viously described [17]. Cells were quantitated using a Alloantibody analysis
1-cm2 grid divided into 100 1-mm2 squares placed in the
Alloantibody production was measured in recipient
eyepiece of a Leitz DMRB microscope (Leica, Heidel-
serum using indirect flow cytometry. Splenocytes wereberg, Germany). Cells were counted in ten randomly
isolated from class I-deficient (H-2b) or class II-deficientselected squares and were scored with the40 objective.
mice (H-2b). One  106 cells were stained per sample.Final counts were expressed as the number of cells per
Cells were treated with Fc-Block (BD Pharmingen) persquare mm (mean  SEM). An individual who was
the manufacturer’s directions, prior to antibody staining,masked to the experimental groups evaluated all sections.
and then stained with phycoerythrin-conjugated anti-
B220 (BD Pharmingen). Cells were then exposed to se-RNA isolation
rial dilutions of recipient serum at 4C for 30 minutes.Total cellular RNA was obtained using standard meth-
Bound IgG was then detected by treating cells withods [18]. Briefly, after the renal clearance study, a portion
FITC-conjugated rat-anti-mouse IgG1 (BD Pharmingen).of the allograft cortex was removed, snap frozen in liquid
Cells were analyzed by flow cytometry, as describednitrogen and stored at70C until use. The frozen tissue
above, evaluating the percent of FITC-positive eventswas homogenized in ice-cold 4 mol/L guanadinium iso-
in the B220 and B220 populations.thiocyanate (Sigma Chemical Company, St. Louis, MO,
USA) using a Polytron homogenizer (Brinkmann Instru-
Statistical analysisments, Westbury, NY, USA). The samples were layered
onto a 5.7 mol/L cesium chloride gradient and centri- Data are presented as the mean  standard error of
fuged at 174,000 g at 20C for 18 hours in a Beckman L7 the mean, except for survival data, which are also pre-
ultracentrifuge (Beckman Instruments, Palo Alto, CA, sented as median survival. For the hemodynamic studies,
USA). The RNA pellets were resuspended in 0.3 mol/L data points for each animal represent the mean of the
sodium acetate, pH 6.0 (Sigma), extracted once with values measured during two clearance periods. Statisti-
1:1 phenol:chloroform, and precipitated in ethanol. The cal significance was assessed using the Student t test or
dried pellet was redissolved in diethylpyrocarbonate- Wilcoxon rank sum test as appropriate.
treated water and the concentration and purity of the
RNA was determined from the absorbance at 260 nm
RESULTSand 280 nm. Samples were stored at 70C until use.
Prolonged survival following transplantation of
RNase protection assay
MHC/ kidney allografts
Cytokine transcripts were quantified using a modifica-
As shown in Figure 1, recipients of control allograftstion of the RNase protection assay previously described
had a median survival of 8.5 days (range 1 to 42 days),[19] using a multiprobe template set (BD Pharmingen,
consistent with results of our previous studies [12, 13].San Diego, CA, USA). Riboprobes were prepared from
In contrast, survival of MHC/ allografts was signifi-MCK template sets containing the cDNA for interleukin
cantly prolonged, with median survival of 42 days (range(IL)-1, IL-1, IL-2, interferon-	 (IFN-	), IL-4, IL-5,
2 to 42 days; P  0.003; Table 1). While only 20% ofIL-6, IL-10, tumor necrosis factor- (TNF-), IL-12p40,
control allograft recipients survived to the study end-IL-12p35, IL-15, and chemokines RANTES (regulated
point of 6 weeks, nearly 80% of recipients of MHC/upon activation, normal T cell expressed and secreted),
allografts survived to this time point. Thus, reduced ex-monocyte chemoattractant protein-1 (MCP-1), macro-
pression of donor MHC antigens on a kidney allograftphage inflammatory protein (MIP)-1 and MIP-1 and
L32 using the In Vitro Transcription kit (BD Pharmin- improves graft survival.
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Fig. 1. Survival of kidney allograft recipients. Recipients were followed Fig. 2. Renal function in transplanted kidneys measured at six weeks
out to six weeks following transplantation. Recipients of MHC/ following transplantation. Isografts ( ), allografts () and MHC/
allografts () had a significantly improved rate of survival than recipi- allografts () are shown. GFR in the experimental groups is expressed
ents of control allografts (), with a median survival time of 42 days in cc/min/kg. GFR was significantly reduced in control allografts com-
versus 8.5 days, respectively (P  0.003). Animals were sacrificed at pared to isografts (*P  0.01). However, GFR was markedly improved
day 42 for renal hemodynamic studies. in MHC/ allografts compared to controls (¶P  0.004), but did not
reach the level of isografts (P  NS).
Table 1. Survival of recipients of kidney allografts
Median survival days previously described [14], control allografts (Fig. 3B)
Experimental group Survival days (meanSEM) demonstrated the characteristic features of chronic rejec-
Control allograft 1, 1, 1, 1, 1, 3, 3, 5, 5, 8.5 (15.32.6) tion including: extensive interstitial and periglomerular
6, 6, 7, 7, 8, 8, 8, 8, fibrosis, perivascular and medial fibrosis, mesangial cell9, 9, 11, 13, 13, 14,
hyperplasia and membranous thickening, as well as a15, 16, 16, 19, 20,
37, 42, 42, 42, 42, 42, diffuse, patchy, chronic inflammatory cell infiltrate.
42, 42
MHC/ allografts similarly demonstrated chronic re-
MHC/ allograft 2, 6, 42, 42, 42, 42, 42, 42 (34.45.1) jection seen in control allografts. However, the severity42, 42, 42, 42
of these changes was markedly reduced (Fig. 3C). To
estimate the severity of these histopathological abnor-
malities, semiquantitative scoring of graft sections was
performed with cumulative scores generated for the indi-Renal function is preserved in
vidual grafts. The mean histologic score in MHC/MHC-deficient allografts
allografts was 13.3  2.1, significantly lower than theWe performed hemodynamic measurements as a
score in control allografts (19.0  1.0; P  0.02). Thequantitative measure of kidney injury. As shown in Fig-
diminished severity of histologic changes was most nota-ure 2, 6 weeks following transplantation, GFR in iso-
ble for reductions in tubular atrophy, and vasculopathy.grafts (6.45  0.53 cc/min/kg; N  5) was similar to that
seen in uninephrectomized mice (7.98  1.62 cc/min/kg)
Immunohistologic and morphometric analyses of[20]. In rejecting control allografts, GFR was substan-
kidney allograftstially depressed (2.19 0.63 cc/min/kg; N 5) compared
The cell surface phenotypes of graft infiltrating cellsto isografts (P  0.01). In contrast, GFR in MHC/
were examined by immunofluorescent staining andallografts (4.92  0.75 cc/min/kg; N  9; P  0.004) was
quantitated by morphometric analysis. Infiltrates in bothsignificantly higher than control allografts. Further, while
control and MHC/ allografts groups consisted pre-GFR in MHC/ allografts tended to be lower than
dominantly of T cells, as shown in Figure 4 A and E. Theisografts, this difference did not achieve statistical sig-
numbers of infiltrating T cells were reduced in MHC/nificance.
grafts. Both CD8 T cells (Fig. 4G; 38.7 2.4 cells/mm2)
Improved histopathology in MHC-deficient allografts and CD4 T cells (Fig. 4F; 38.3  4.4 cells/mm2) were
significantly reduced in MHC/ grafts compared toAs shown in Figure 3A, the histology of isografts six
controls (Fig. 4C, 96  11.4 CD8 T cells/mm2, P weeks following transplantation was essentially normal,
with little fibrosis or inflammation. In contrast, as we have 0.008; and Fig. 4B, 75  6.6 CD4 T cells/mm2, P 
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0.008). Despite this reduction in T cell infiltration, the
relative number of CD4 to CD8 cells was similar in both
controls and MHC/ allografts (CD4/CD8 0.95 and
0.81, respectively). Numerous macrophages were pres-
ent in both allografts groups, but again, the numbers in
MHC/ grafts (Fig. 4H; 60  6.9 cell/mm2) were less
than controls (Fig. 4D; 134  23.0 macrophages/mm2,
P  0.04). Thus, the absence of donor MHC expression
significantly reduces the immune cell infiltrate in kidney
allografts.
Cytokine mRNA expression is reduced in MHC/
kidney allografts.
To characterize in situ T cell function, intragraft ex-
pression of cytokines at 6 weeks post-transplantation was
evaluated by RNase protection assay (RPA; described in
the Methods section). Expression of pro-inflammatory
cytokines IL-2, IFN-	, IL-1, TNF-, and IL-6 were simi-
lar between allograft groups. However, expression of
Th2 cytokines IL-4, IL-5, and IL-10 were 32 to 72% lower
in MHC/ allografts compared to controls (Table 2).
Expression of transforming growth factor (TGF)-2 and
TGF-3, fibrogenic cytokines posited to be important in
the development of CR [14, 21], were modestly, but
significantly enhanced in MHC/ allografts compared
to controls (P  0.05), while TGF-1 was similar to
controls. Thus, the absence of MHC antigens on donor
tissue significantly alters the intragraft expression of Th2
cytokines. Furthermore, despite enhanced expression of
some TGF- isoforms, the severity of CR was reduced
in MHC/ allografts.
Alloantibody production is absent in recipients of
MHC/ allografts
Anti-donor antibodies in the serum of transplant re-
cipients were measured by indirect flow cytometry. Sig-
nificant titers of anti-donor MHC class I H-2b (Fig. 5A)
were detected in recipients of control allografts but not
MHC/ grafts. Similarly, antibody against MHC class
II IAb (Fig. 5B) was detected in controls but not
MHC/ grafts. Isografted recipients demonstrated
neither MHC class I nor II antibodies.
To further analyze the functional nature of serum anti-
Fig. 3. Masson-trichrome stained sections of kidney allografts six body production, sections of allografts were stained to
weeks after transplantation. (A) Relatively normal tissue was seen in
detect IgG, IgM and C3. In control allografts, there wasisografts. (B) Control allografts demonstrated the typical histologic
features of chronic rejection. (C) While chronic rejection features were substantial IgG within glomeruli and on tubules, with
seen in MHC/ allografts, the severity of these changes was markedly occasional cytoplasmic staining (Fig. 6E). IgM was ex-
reduced compared to controls.
pressed heavily throughout the glomerulus (Fig. 6F),

Fig. 4. Immunofluorescence staining for T cell markers in kidney allografts, four weeks post-transplantation. Cellular infiltrates consisting of T
cells were detected using antibody against Thy1.2 in both control (A) and MHC/ allografts (E). While numerous CD4 T cells were seen in
control allografts (B), fewer CD4 cells were detected in MHC/ allografts (F ). Similarly, there was a reduction in the infiltration by CD8 T
cells in MHC/ grafts (G) compared to controls (C ). Macrophages were abundant in control allografts (D), but were reduced in MHC/
allografts (H).
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Table 2. Cytokine mRNA expression in 6-week kidney allografts response of recipients to MHC/ allografts was the
virtual absence of alloantibodies. While the role of anti-Cytokine MHC/ allografts Control allografts
body in acute rejection has been debated, there is sub-IL-2 181.918.5 212.814.5
IFN-	 526.759.1 502.836.5 stantial evidence supporting the detrimental effects of
IL-4 35.95.8a 109.012.9 anti-donor antibodies [reviewed in 22]. Alloantibodies
IL-5 59.28.0b 135.713.6
may mediate injury, either directly, or through activationIL-10 147.719.2c 204.622.3
TGF-1 494.751 553.822.2 of other pro-inflammatory mediators. The role of pre-
TGF-2 395.155.2d 247.65.5 formed anti-donor antibodies in graft dysfunction in hyp-
TGF-3 554.334.0d 473.022.1
eracute rejection is incontrovertible [22, 23] and the sub-
All values are normalized to L32 expression; data are meanSEM. sequent development of anti-donor antibodies followinga P  0.003 compared to control allografts
b P  0.002 compared to control allografts transplantation can be harmful [22, 24–27]. Moreover,
c P  0.05 compared to control allografts the absence of anti-donor antibodies has been associatedd P  0.03 compared to control allografts
with reduced incidence of chronic rejection [28–31].
Based on these studies, we posit that the absence of
alloantibodies in recipients of MHC/ allografts re-
with modest C3 within the glomerulus and tubules (Fig. sults in the protection against CR observed in MHC/
6G). Thus, donor alloantigen stimulates the production allografts, which translates in improved graft and recipi-
of antibodies that are deposited within the graft and ent survival. Moreover, these data support the critical
associated with complement deposition. In contrast, de- importance of intact donor antigen expression on the
tectable IgG was virtually absent in all MHC/ allo- development of a humoral alloimmune response.
grafts (Fig. 6A). Only faint deposition of IgM was de- Similar to the effect on the humoral response, the
tected in the mesangium and along glomerular capillaries cellular immune responses to MHC-deficient allografts
(Fig. 6B). Complement (Fig. 6C) was seen faintly and dif- also were attenuated compared to controls. In the infil-
fusely along basement membrane and segmentally within trates of MHC/ allografts, there are strikingly fewer
the mesangium, but at levels that were substantially less T cells and macrophages during the course of rejection.
than in control allografts. Thus, the absence of donor This is consistent with previous studies suggesting that
MHC antigens confers reduced antibody-associated allo- donor MHC expression regulates the accumulation of
graft injury. immune cells within the grafts. For example, reduction
of donor MHC class I expression reduced the quantity
of CD8 T cells infiltrating the graft [13], while the ab-
DISCUSSION sence of MHC class II alters CD4 T cell infiltration
In these studies, the combined absence of donor ex- [32]. In this case, deficiency of all MHC antigens caused
pression of MHC class I and II antigens dramatically a proportional reduction in both CD4 and CD8 T cells.
improved the function and survival of kidney allografts Impaired intra-graft accumulation of lymphocytes may
and reduced the histologic severity of chronic rejection. be due to reduced antigen load to the extent that graft
Additionally, there were marked differences in the char- antigen serves as a stimulus for T cell migration. Alterna-
acter of the immune response toward MHC/ allo- tively, donor dendritic cells lacking MHC class I and class
grafts, including reduced numbers of infiltrating T cells II may be unable to adequately activate lymphocytes in
and macrophages, reduced expression of Th2 cytokines, peripheral lymphoid tissues and thereby facilitate their
and significantly, the absence of a detectable humoral ability to home to the graft [33]. The relative contribution
response toward the allograft. Thus, abrogation of donor of MHC antigens on parenchymal cells versus dendritic
MHC expression reduces the immunogenicity of the cells to the regulate accumulation of lymphocytes in the
graft and strongly influences the character and severity allograft cannot be determined by the current studies.
of chronic rejection of kidney grafts. Similarly, the paren- However, this issue could be addressed by rescuing cell-
chymal damage and injury in MHC/ grafts during specific expression of MHC antigens in deficient mice
acute allograft rejection three weeks after transplantation and studying the contribution of MHC expression on
were significantly reduced compared to wild-type allo- individual cell populations to regulate T cell infiltration
grafts (abstract; Mannon et al, J Am Soc Nephrol 8:660A, into allografts. Thus, the absence of donor MHC antigens
1997). The diminished early injury likely leads to a reduc- affects both humoral and cellular components of the
tion in the later development of fibrosis and atrophy. immune response to an allograft.
Thus, in the context of previous studies, our results sup- Cytokine expression, which reflects the nature and
port the notion that responses directed toward MHC intensity of the intra-graft immune response, also was
antigens expressed on donor cells make a significant con- substantially altered in MHC-deficient kidney allografts.
tribution to the pathogenesis of CR. For instance, we found modest but significant reductions
in Th2 cytokines IL-4, IL-5 and IL-10 in MHC/ allo-One of the most striking differences in the immune
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Fig. 5. Alloantibody titration in recipients of
kidney allografts showing (A) IgG binding to
MHC class I H-2b and (B) IgG binding to
MHC class II Iab. The percent of lymphocytes
bound by recipient serum and detected with
anti-mouse IgG is shown on the vertical axis.
Sera from control allograft recipients () con-
tained IgG antibodies against H-2b (A) and
IAb (B), and the binding titrates out over the
dilution range tested. In contrast, sera from
recipients of MHC/ allografts () did not
produce detectable anti H-2b or IAb antibod-
ies. Sera from isografted mice () are shown
for comparison.
grafts compared to controls. This is similar to our findings donor and recipient. Additionally, free Db heavy chain
on the cell surface of MHC/ mice is sufficient to in-in allografts with isolated MHC class II deficiency [32].
A predominant Th1 response has been suggested to pro- duce a cellular immune response. In studies of 2-micro-
globulin–deficient mice, Db class I heavy chains are pres-mote rejection and graft injury [34–37], and Th2 re-
sponses have been associated with prolonged graft sur- ent on the cell surface of lymphocytes and other tissues
[48]. These chains induce T cell cytotoxicity [48, 49] andvival and tolerance induction [36–38]. Our data are
consistent with recent studies that have argued against allow for the positive selection of a small number of CD8
T cells within the thymus [50, 51]. In skin transplanta strict functional delineation of Th1 cytokines as detri-
mental and Th2 cytokines as beneficial in rejection [39– models, Lee et al have demonstrated that such “leaki-
ness” of class I expression results in CD8 T cell allorec-42]. While the cytokine milieu is altered in MHC/
allografts, it is difficult to quantitate the relative contribu- ognition and rejection of skin allografts, dependent on
CD4 T cells sensitized indirectly to donor-derived pep-tion of these changes to the improved function and sur-
vival of MHC/ grafts. Alternatively the absence of tides [11, 52, 53]. While these mechanisms depend on
direct allorecognition, we cannot exclude the contribu-alloantigen to stimulate an appropriate allo-antibody
within the recipient may be a primary mechanism de- tion of indirect recognition. Finally, non-immunologic
contributions to CR, such as disparity between donortermining the improved function and prolonged survival
of the MHC-deficient grafts. and recipient renal mass and size, do not appear to be
operating, as isografted animals have normal graft histol-Up-regulation of TGF- has been associated with the
development of acute rejection [43, 44] and CR in a ogy and function.
The elimination of MHC antigen expression by genevariety of animal models [14, 45] and in humans [re-
viewed in 46]. We have previously found that this up- targeting is not practical as a clinical maneuver in kidney
transplantation. Nonetheless, our studies suggest thatregulation was blunted in MHC class I deficient or class
II deficient kidney allografts and yet had no impact on reducing donor MHC expression may be useful in amel-
iorating graft injury. These approaches might includethe pathological changes in CR [14]. Interestingly, in
this study, we found no difference in intragraft mRNA small molecules or antisense oligonucleotides that may
target regulatory proteins in MHC expression such asexpression for TGF-1 between groups and modest but
significant increases in the expression of TGF-2 and -3 Class II transactivator [54] or that target proteins that
regulate peptide loading onto MHC such as TAP (trans-isoforms in MHC/ allografts compared to controls.
While the biological effects of these isoforms are associ- porters associated with antigen processing) [42]. Further-
more, we suggest that gene targeting approaches thatated with the promotion of chronic graft injury in humans
[21, 47], our results support the notion that there may more effectively alter MHC expression by disrupting of
class I heavy chains [42, 55], or by deleting transcriptionbe altered receptor expression within allograft groups,
or expression of other factors that lead to collagen depo- factors that regulate MHC expression [56] might have
an even more profound effect in animal models.sition within CR grafts in this model.
While the functional and histopathological manifes- In conclusion, absence of normal expression of MHC
on a donor organ graft protects against the developmenttations of CR are reduced in MHC/ grafts, they are
not completely absent. The persistence of significant of CR. There is a profound absence of humoral responses
toward these grafts, and a reduction in cellular responseschronic injury despite the absence of donor MHC anti-
gens may be due to minor antigen disparities between toward allografted tissue. These results demonstrate the
Mannon et al: MHC expression and allograft rejection298
Fig. 6. Alloantibody deposition in renal allografts detected by immunofluorescence. MHC/ allografts demonstrated little IgG (A), IgM (B),
and C3 (C). In control allografts, IgG (E), IgM (F ), or C3 (G) were present within glomeruli.
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